Press releases
- Live from ASCO 2024 | Oral Report Released Latest Data of Olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3%
- Live from ASCO 2024 | Ascentage Pharma Releases Updated Data Showing Promising Efficacy and Safety of Lisaftoclax in Patients with WM
- Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety
- Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLC
- ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates
- EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress
- ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST
- AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting
- Ascentage Pharma Announces 2023 Annual Results
More ▼
Key statistics
As of last trade, Ascentage Pharma Group International (36X:FRA) traded at 2.38, 27.96% above the 52 week low of 1.86 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.38 |
---|---|
High | 2.38 |
Low | 2.38 |
Bid | 2.38 |
Offer | 2.58 |
Previous close | 2.42 |
Average volume | 250.86 |
---|---|
Shares outstanding | 290.22m |
Free float | 212.90m |
P/E (TTM) | -- |
Market cap | 5.80bn HKD |
EPS (TTM) | -3.53 HKD |
Data delayed at least 15 minutes, as of Jun 10 2024 08:59 BST.
More ▼